•
Dec 31, 2021
Bioxcel Therapeutics Q4 2021 Earnings Report
BioXcel Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2021, highlighting the near approval of BXCL501 and the progression of Alzheimer's and MDD programs.
Key Takeaways
BioXcel Therapeutics reported a net loss of $26.1 million for the fourth quarter of 2021, compared to a net loss of $21.1 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents totaled approximately $233.0 million.
Nearing potential approval for BXCL501, focusing on launch readiness.
Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease
Submitted IND to evaluate BXCL501 as adjunctive treatment for major depressive disorder (MDD)
Demonstrated encouraging composite response rates for BXCL701 in combination with KEYTRUDA® for mCRPC in SCNC and adenocarcinoma cohorts